tbuckley/cabot-search huggingface dataset:
AB0342 The chronic hand pain in rheumatoid arthritis, osteoarthritis, and fibromyalgia: the role of central sensitisation
Authors: F.F. Ayhan, M.A. Güler, Ö. F. Çelik
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Modern pain medicine divided chronic pain as nociceptive, neuropathic, central sensitisation (CS) and mixed pain. CS syndromes are a group of disorders characterised by chronic non-neuropathic and non-nociceptive pain(.<sup>1</sup> Central sensitisation inventory (CSI) suggest the tool generates reliable and valid data that quantify the severity of several symptoms of CS.<sup>2</sup> <h3>Objectives</h3> Hand pain in RA, OA, and FMS have different features. The aim of this study was to show the role of CS pain in these patients. <h3>Methods</h3> Totally 151 patients with chronic hand pain (56 RA, 45 OA, and 50 FMS) were included. CSI was used for evaluation of CS.<sup>2,3</sup> CSI consists of 2 parts: CSI-A scoring 0–100 and CSI-B including 10-CS related syndromes (restless leg, chronic fatigue, fibromyalgia, temporomandibular disorders, migraine/tension type headache, irritable bowel, multiple chemical sensitivity, whiplash, anxiety/panic attack, and depression). <h3>Results</h3> Sixteen patients (28.57%) had active (DAS28 ≥2.6) RA. Disease activity was not related with CSI-A and CSI-B scores. Rheumatoid hands was less painful compared with them of OA and FMS (p&lt;0.001). The CS pain was detected in most of the patients with FMS, compared with OA and RA patients (p&lt;0.001). Similarly, CSI-A score was the highest in patients with FMS group (p&lt;0.001) and similar in both OA and RA groups (p&gt;0.05). CS-related syndromes were also detected in both RA and OA groups, but less than FMS group (p&lt;0.005). The numbers of CS syndromes were similar in both RA and FMS (p=0.084) and higher than OA group (p=0.036). Table 1 shows the demographic and pain parameters in all groups. CSI-A score was correlated with VAS-pain score (r=0.364, p&lt;0.001). <h3>Conclusions</h3> Central sensitisation should be considered in patients with chronic persistent pain, not only having FMS, but also half of the patients having RA and OA. It is not a rare phenomenon and if it is exists, effective pain management strategies could be needed in addition to the specific pharmacologic treatment. <h3>References</h3> [1] O'Leary H, et al. Nervous System Sensitization as a Predictor of Outcome in the Treatment of Peripheral Musculoskeletal Conditions: Pain Pract2017;17(2):249–266. [2] Neblett R, et al. The CSI. The Journal of Pain2013;14(5):438–45. [3] Düzce E. SS Ölçeğinin Türkçe Geçerlilik&amp;Güvenilirliği. Trakya FTR Uzmanlık Tezi2017. <h3>Disclosure of Interest</h3> None declared
The Chest Australia Trial: a randomised controlled trial of an intervention to increase consultation rates in smokers at risk of lung cancer
Authors: Jon D Emery, Sonya R Murray, Fiona M Walter, Andrew Martin, Stephen Goodall, Danielle Mazza, Emily Habgood, Yvonne Kutzer, David John Barnes, Peter Murchie
Journal: Thorax (2019)

Background International research has focused on screening and mass media campaigns to promote earlier patient presentation and detect lung cancer earlier. This trial tested the effect of a behavioural intervention in people at increased risk of lung cancer on help-seeking for respiratory symptoms. Methods Parallel, individually randomised controlled trial. Eligible participants were long-term smokers with at least 20 pack-years, aged 55 and above. The CHEST intervention entailed a consultation to discuss and implement a self-help manual, followed by self-monitoring reminders to encourage help-seeking for respiratory symptoms. The control group received a brief discussion about lung health. Both groups had baseline spirometry. Telephone randomisation was conducted, 1:1, stratified Medical Research Council (MRC) dyspnoea score and general practice. Participants could not be blinded; data extraction and statistical analyses were performed blinded to group assignment. The primary outcome was respiratory consultation rates. Results We randomised 551 participants (274 intervention, 277 control) from whom the primary outcome was determined for 542 (269 intervention, 273 control). There was a 40% relative increase in respiratory consultations in the intervention group: (adjusted rates (95% CI) intervention 0.57 (0.47 to 0.70), control 0.41 (0.32 to 0.52), relative rate 1.40 (1.08 to 1.82); p=0.0123). There were no significant differences in time to first respiratory consultation, total consultation rates or measures of psychological harm. The incremental cost-effectiveness ratio was $A1289 per additional respiratory consultation. Conclusions A behavioural intervention can significantly increase consulting for respiratory symptoms in patients at increased risk of lung cancer. This intervention could have an important role in primary care as part of a broader approach to improve respiratory health in patients at higher risk. Trial registration number Australian New Zealand Clinical Trial Registry (1261300039 3752). This was registered pre-results.
Single Cell Transcriptome in Chronic Myeloid Leukemia (CML): Pseudotime Analysis Reveals a Rare Population with Embryonic Stem Cell Features and Druggable Intricated Transitional Stem Cell States
Authors: Sarah Pagliaro, Christophe Desterke, Herve Acloque, Annelise Bennaceur-Griscelli, Ali G Turhan
Journal: Blood (2018)
Left Ventricular Remodeling in ST-Segment Elevation Myocardial Infarction Patients With Depressed Left Ventricular Ejection Fraction After Cardiac Rehabilitation
Authors: Sylvain Grall, Romain Bouteau, Jean-François Hamel, Gabriel Garcia, Hermeland Delagarde, Serge Willoteaux, Valérie Dubus, Fabrice Prunier, Alain Furber, Loïc Bière
Journal: JACC. Cardiovascular imaging (2019)
Militaries and global health: peace, conflict, and disaster response
Authors: Joshua Michaud, Kellie Moss, Derek Licina, Ron Waldman, Adam Kamradt-Scott, Maureen Bartee, Matthew Lim, Jamie Williamson, Frederick Burkle, Christina S Polyak, Nicholas Thomson, David L Heymann, Louis Lillywhite
Journal: The Lancet (2019)
SAT0392 The relevance of serum procalcitonin quantification for differential diagnosis of infections and rheumatic diseases
Authors: A. Dilbaryan, B. Belov, G. Tarasova, D. Bukhanova
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Assessment of procalcitonin (PCT) serum levels is of great interest in current rheumatology practice, due to clinical and laboratory similarity of acute systemic rheumatic diseases (RDs) and acute infectious process, and because of low diagnostic yield of conventional ESR, CRP and WBC in active RDs. <h3>Objectives</h3> To evaluate the relevance of PCT as a specific marker of generalised and local infections in patients with RDs. <h3>Methods</h3> Medical records of 134 in-hospital patients (mean age 40,6±19,5) admitted to VA Nasonova Research Institute of Rheumatology for examination and treatment were analysed in this retrospective study. Serum PCT concentration was measured using quantitative electrochemiluminescence method, Cobas E 411 analyzer (Roshe, Switzerland). The infectious process was diagnosed in 75 pts, generalised – in 4, and local – in 71. Based on the severity of fever and intoxication local infections were divided into mild – 41 cases, and severe – 30 cases. <h3>Results</h3> The PCT level reached &gt;2.0 ng/mL in 3 of 4 cases in generalised infection. In population with severe local infections (n=30) the PCT concentration exceeded the threshold and amounted to 0.60 ng/mL [0.19; 1,84], while in pts with mild infection (n=41) it was 0.13 ng/mL [0,08; 0,25] (table 1). PCT levels positively correlated with ESR, CRP, white blood cell count, and SLE activity according to SLEDAI index in this retrospective study. Maximal PCT levels were found in adult-onset Still's disease (ASD) pts with high activity of rheumatic process without underlying infection – 0.26 [0.10;0,61] ng/mL. The test's sensitivity and specificity in generalised/severe local infections group (n=34) were 60% and 82,5%, respectively, with a threshold value of 0.4 ng/mL. <h3>Conclusions</h3> PCT quantification is a sensitive and specific method for differential diagnosis of serious bacterial infections in patients with different activity of systemic RD. ASD seems to be the exception, as it was associated with PCT increase in the absence any infection. Further studies are needed to determine PCT thresholds for different RDs. <h3>Disclosure of Interest</h3> None declared
Ruxolitinib in Combination with Dasatinib and Dexamethasone Is an Active and Well-Tolerated Chemotherapy-Sparing Oral Induction Regimen for Adults with Philadelphia Chromosome-Positive ALL: Results of a Phase I Trial
Authors: Mark Blaine Geyer, Patrick W. Burke, Amber C. King, Michael J. Mauro, Martin S. Tallman, Ross L. Levine, Charles J. Sherr, Dan Douer, Jae H. Park
Journal: Blood (2018)
AB0615 Changes in somatosensory evoked potentials in patients with primary sjogren’s syndrome
Authors: E. Dziadkowiak, A. Sebastian, M. Wieczorek, E. Kusińska, M. Waliszewska-Prosół, P. Wiland, M. Ejma
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Primary Sjogren's syndrom (pSS) is a chronic autoimmune disease, which, in addition to impaired function of exocrine glands, can affect other organs including nervous system. <h3>Objectives</h3> The aim of the study was to establish whether in patients with pSS without central nervous system (CNS) involvement, the function of the central portion of the sensory pathway can be challenged. <h3>Methods</h3> In 33 patients diagnosed with pSS without clinical features of CNS damage and normal head CT scan, somatosensory evoked potentials (SEP) were studied. The results were compared to other clinical parameters of the disease, particularly to immunological status. The control group consisted of 20 healthy volunteers selected with respect to age and sex. <h3>Results</h3> Mean latency of all components of SEP were considerably prolonged in patients compared to the control group. Mean interpeak latency N20-N13 (duration of central conduction TT) did not differ significantly between the groups. However, in the study group, mean amplitude of N20P22 and N13P16 was significantly higher compared to healthy individuals. In patients with PSS, significant differences in SEP parameters depending on duration of the disease, duration of arthralgia and presence of SSA and SSB antibodies were noted. No significant differences in mean SEP parameters were observed with respect to skin lesions, xerophthalmia, current joint pain and swelling, focus score, levels of C3 and C4 complement components, ESR, CRP and presence of Ro52 antibodies. <h3>Conclusions</h3> The authors confirmed central nervous system involvement often observed in patients with pSS. They also showed dysfunction of the central sensory neuron as a difference in amplitude of cortical response, which indicates subclinical damage to the CNS. <h3>Disclosure of Interest</h3> None declared
Adenosine A2B Receptor Controls Erythroid Lineage Commitment in Stress Erythropoiesis By Promoting Metabolic Reprogramming
Authors: Hong Liu, Rongrong Liu, Travis Nemkov, Jacob Couturier, Long Liang, Anren Song, Shushan Zhao, Kaiqi Sun, Morayo Adebiyi, Yuan Edward Wen, Alexander Wen, Jing Liu, Rodney Kellems, Angelo D'Alessandro, Michael Blackburn, Yang Xia
Journal: Blood (2018)
Effect of Histologic Grade on Clinical Outcomes of Follicular Lymphoma: Prolonged Progression Free Survival of Grade 3 Follicular Lymphoma in the Rituximab Era
Authors: Suchitra Sundaram, Erika Moore, Sabarish Ayyappan, Fahrettin Covut, Benjamin Tomlinson, Richard Creger, Ehsan Malek, Leland Metheny, Brenda W. Cooper, Hillard M Lazarus, Marcos de Lima, Paolo Caimi
Journal: Blood (2017)
Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
Authors: R. Sundar, K.K. Huang, A. Qamra, K.-M. Kim, S.T. Kim, W.K. Kang, A.L.K. Tan, J. Lee, P. Tan
Journal: Annals of Oncology (2019)

Utilization of alternative transcription start sites through alterations in epigenetic promoter regions causes reduced expression of immunogenic N-terminal peptides, which may facilitate immune evasion in early gastric cancer. We hypothesized that tumors with high alternate promoter utilization would be resistant to immune checkpoint inhibition in metastatic gastric cancer.Two cohorts of patients with metastatic gastric cancer treated with immunotherapy were analyzed. The first cohort (N = 24) included patients treated with either nivolumab or pembrolizumab. Alternate promoter utilization was measured using the NanoString® (NanoString Technologies, Seattle, WA, USA) platform on archival tissue samples. The second cohort was a phase II clinical trial of patients uniformly treated with pembrolizumab (N = 37). Fresh tumor biopsies were obtained, and transcriptomic analysis was carried out on RNAseq data. Alternate promoter utilization was correlated to T-cell cytolytic activity, objective response rate and survival.In the first cohort 8 of 24 (33%) tumors were identified to have high alternate promoter utilization (APhigh), and this was used to define the APhigh tertile of the second cohort (13 APhigh of 37). APhigh tumors exhibited decreased markers of T-cell cytolytic activity and lower response rates (8% versus 42%, P = 0.03). Median progression-free survival was lower in the APhigh group (55 versus 180 days, P = 0.0076). In multivariate analysis, alternative promoter utilization was an independent predictor of immunotherapy survival [hazard ratio 0.29, 95% confidence interval 0.099-0.85, P = 0.024). Analyzing tumoral evolution through paired pre-treatment and post-treatment biopsies, we observed consistent shifts in alternative promoter utilization rate associated with clinical response.A substantial proportion of metastatic gastric cancers utilize alternate promoters as a mechanism of immune evasion, and these tumors may be resistant to anti-PD1 immune checkpoint inhibition. Alternate promoter utilization is thus a potential mechanism of resistance to immune checkpoint inhibition, and a novel predictive biomarker for immunotherapy.ClinicalTrials.gov Identifier: NCT#02589496.
FRI0622 Trends in encounters with rheumatologists in a publicly-funded single payer healthcare system
Authors: J. Widdifield, S. Bernatsky, V. Ahluwalia, C. Barber, L. Eder, B. Kuriya, V. Ling, A. Lyddiatt, M. Paterson, J. Pope, C. Thorne
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Rheumatology workforces are challenged by too few physicians, increasing incidence and prevalence of MSK diseases (and complexity of co-morbid conditions) in aging populations, and expanding therapeutic options that increase demand for service. Understanding trends in rates of rheumatology encounters with new and existing patients will help to identify why patients have delays to rheumatology care and mobilize efforts to help meet patients' needs. <h3>Objectives:</h3> To describe trends in patient encounters with rheumatologists over time in Ontario, Canada. <h3>Methods:</h3> We analyzed administrative health data from 2000 to 2013 in Ontario, Canada, where all 13 million residents are covered by a publicly-funded healthcare system and access to rheumatologists is dependent upon referrals. During this time, Ontario had a stable rheumatology supply of 1 rheumatologist per 75,000 population (0.7 FTEs/75,000). We determined annual incident, follow-up and total patient encounters seen by rheumatologists. Rates were calculated using the total population of Ontario residents 18 and older, each year. Diagnosis codes assigned at each encounter were used to assess changes in the case-mix of patients under rheumatology care over time. <h3>Results:</h3> From 2000 to 2013, the proportion of all Ontario residents seen by rheumatologists was constant over time (2.7%). The total number of rheumatology encounters increased from 561,452 to 742,952 but the total encounter rate remained relatively stable over time (table 1). The annual new consultation rate significantly declined over time from 1.6 to 0.8 new patients per 100 population. Both the annual proportion of incident patients and the ratios of incident to established patients and incident to total patient encounters declined significantly over time. We observed a shift in the diagnostic case-mix over time: encounter rates for systemic inflammatory conditions significantly increased over time and encounter rates for non-systemic conditions (OA, regional MSK conditions) decreased. The volume of rheumatoid arthritis (RA) encounters increased the most, with 17% of all rheumatology encounters related to RA in 2000 versus 32% in 2013. <h3>Conclusions:</h3> The significant decline in new patient consultation rates over time helps illustrate the growing supply-demand mismatch in rheumatology care. An increasing fraction of rheumatology encounters in Ontario are with established patients, which may be limiting access for new consultations and increasing wait times. We also observed a shift in the patient case-mix over time with rheumatologists seeing/prioritizing more systemic inflammatory conditions. Our findings provide new inputs for rheumatology workforce planning models. <h3>Disclosure of Interest:</h3> None declared
Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial
Authors: Tim H. Brummendorf, Carlo Gambacorti-Passerini, Andreas Hochhaus, Jeff H. Lipton, Vamsi Kota, Michael W. Deininger, Eric Leip, Andrea Viqueira, Roxanne Ferdinand, Jorge E. Cortes
Journal: Blood (2018)
<i>Notes from the Field:</i> Typhoid Fever Outbreak — Harare, Zimbabwe, October 2017–February 2018
Authors: Hammad S. N’cho, Kudzai P.E. Masunda, Innocent Mukeredzi, Portia Manangazira, Emmaculate Govore, Clemence Duri, Rachael D. Aubert, Haley Martin, Elizabeth Gonese, Michael Vere, Beth A. Tippett Barr, Shirish Balachandra, Jonathan Strysko, William W. Davis, Grace D. Appiah, Eric Mintz
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

On October 16, 2017, after identifying a suspected typhoid fever case in a resident of Mbare suburb in Harare, Zimbabwe, the city health department investigated further and, as of February 24, 2018, had identified a total of 3,187 suspected cases.
OP0063 Peripheral arterial disease and risk of osteoporotic hip fracture: a systematic review and meta-analysis of cohort studies
Authors: P. Ungprasert, K. Wijarnpreecha, C. Thongprayoon, W. Cheungpasitporn
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Previous studies have demonstrated that patients with peripheral arterial disease (PAD) had lower bone mineral density, particularly in the femur, compared with general population. Therefore, it is possible that patients with PAD may have a higher risk of osteoporotic hip fracture. <h3>Objectives</h3> To compare the risk of developing hip fracture between patients with PAD and individuals without PAD. <h3>Methods</h3> A systematic literature search was conducted using EMBASE and MEDLINE database from inception to November 2017 to identify all cohort studies that investigated the risk of incident hip fracture among patients with PAD compared with individuals without PAD. The systematic literature review was independently conducted by the first two investigators using the search strategy that included the terms for 'peripheral arterial disease' and 'hip fracture'. Eligible studies must be cohort studies (either prospective or retrospective) that reported the risk of incident hip fracture among patients with PAD. Comparators must be individuals without PAD. Eligible studies must provide the effect estimates (relative risks (RR) or hazard ratios (HR)) with 95% confidence intervals (CI) for the calculation of pooled effect estimates. Adjusted point estimates from each study were combined togetehr using the random-effect, generic inverse variance method as described by DerSimonian and Laird. <h3>Results</h3> Of 8464 retrieved articles, 6 cohort studies (3 prospective cohort studies and 3 retrospective cohort studies) involving 15 895 patients with PAD and 2 33 835 comparators without PAD met the eligibility criteria and were included in the meta-analysis. We found a significantly increased risk of incident hip fracture among patients with PAD compared with individuals without PAD with the pooled RR of 1.64 (95% CI: 1.17 to 2.29). The statistical heterogeneity was high with an I<sup>2</sup> of 80%. Subgroup analysis by study design showed a significantly increased risk of incident hip fracture among patients with PAD for both prospective studies (pooled RR 1.60; 95% CI: 1.12 to 2.28; I<sup>2</sup>0%) and retrospective studies (pooled RR 1.72; 95% CI: 1.07 to 2.77; I<sup>2</sup>92%) as shown in figure 1. <h3>Conclusions</h3> In summary, this study demonstrated a significantly increased risk of incident hip fracture among patients with PAD compared with individuals without PAD. <h3>Disclosure of Interest</h3> None declared
AB0665 Interstitial lung disease among patients with giant cell arteritis
Authors: H. Tamaki, T. Jinta, M. Okada
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Lately interstitial lung disease (ILD) has been recognised more and more as a manifestation of primary systemic vasculitis, particularly among patients with microscopic polyangiitis (MPA), which is predominantly a disease of the elderly in Japan. Another primary systemic vasculitis that occurs frequently in the elderly is Giant Cell Arteritis (GCA) and one of the unusual manifestations of GCA includes non-productive cough that can occur in about 10% of patients. It is speculated that vasculitis in the area of cough receptors results in this manifestation. There have been only anecdotes about the association of GCA with ILD and it is unknown whether ILD is truly prevalent in patients with GCA. <h3>Objectives</h3> Here we systematically reviewed chest images of patients with GCA and investigated the prevalence of CT scan abnormality consistent with ILD among patients with GCA. <h3>Methods</h3> Single centre retrospective chart review was conducted at St. Luke's International Hospital in Tokyo. The charts of patients with the diagnosis of GCA who were seen from March 2004 till August 2017 were extracted. The clinical data were obtained. Pulmonary images were reviewed by one of the authors, who is a pulmonologist and characteristics of the pulmonary lesions based on computed tomography (CT) of the lung were recorded. <h3>Results</h3> Forty-six patients had a diagnosis of Giant Cell Arteritis. Thirty-nine of them had a chest CT scan. The mean age of the patients was 69±17 years and 27 patients (58%) were female. Ten patients (26%) had abnormality in the CT scan. The abnormality included linear infiltrates beneath the posterior aspect of the pleura in the lung bases (n=9), ground glass opacities (n=3), honeycombing (n=3), and reticulonocular infiltrates (n=2). Two patients received prednisolone for ILD, ILD of whom were stable. No patients died during the median follow up of 14.5 months. <h3>Conclusions</h3> Chest CT abnormality consistent with mild ILD was prevalent among patients with GCA. The prognosis of these patients appears to be favourable and these patients responded to prednisolone. <h3>Disclosure of Interest</h3> None declared
Abstract 16207: Progression From Paroxysmal to Sustained Atrial Fibrillation as an Increased Risk of Hospitalization for Heart Failure: The Fushimi Af Registry
Authors: Hisashi Ogawa, Yoshimori An, Mitsuru Ishii, Moritake Iguchi, Masahiro Esato, Yeong-Hwa Chun, Hiromichi Wada, Koji Hasegawa, Mitsuru Abe, Masaharu Akao
Journal: Circulation (2016)

Background: Atrial fibrillation (AF) increases the risks of hospitalization for heart failure as well as thromboembolism. Progression from paroxysmal to sustained types (persistent or permanent) of...